Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120896 | 0.97 | — | — | |
| Phosphine SCHEMBL4870393 | 0.94 | IDO1 (0.52) | IDO1LMNACYP2A6TAAR1AGXT | |
| Methane SCHEMBL28356057 | 0.94 | IDO1 (0.52) | IDO1LMNACYP2A6TAAR1AGXT | |
| SCHEMBL4989141 | 0.94 | IDO1 (0.52) | IDO1LMNACYP2A6TAAR1AGXT | |
| Hydrochloric Acid SCHEMBL11121998 | 0.94 | IDO1 (0.52) | IDO1LMNACYP2A6TAAR1AGXT | |
| SCHEMBL8992968 | 0.88 | IDO1 (0.48) | IDO1LMNACYP2A6TAAR1AGXT | |
| SCHEMBL2069301 | 0.88 | MAOB (0.54) | IDO1LMNACYP2A6TAAR1AGXT | |
| SCHEMBL16663974 | 0.88 | TAAR1 (0.56) | IDO1LMNACYP2A6TAAR1AGXT | |
| SCHEMBL28574743 | 0.84 | RAB9A (0.52) | IDO1TAAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL97582 | 0.83 | CA1 (0.52) | IDO1TAAR1AGXTSLC6A4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2017-10-05 | — | — | US | disclosed |
| CN-105008344-B | Bruton's tyrosine kinase inhibitor | 辉瑞公司 | 2017-07-25 | — | — | CN | disclosed |
| EP-2604260-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SHIONOGI & CO (JP) | 2017-05-10 | — | — | EP | disclosed |
| EP-2914586-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160052892-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | SHIONOGI & CO (JP) | 2016-02-25 | — | — | US | disclosed |
| US-9212130-B2 | Heterocyclic derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2914586-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Pfizer Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| CN-103492376-B | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LTD | 2015-07-22 | — | — | CN | disclosed |
| CN-102480964-B | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME | 2015-07-08 | — | — | CN | disclosed |
| WO-2014068527-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20130225596-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | SHIONOGI & CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2604260-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi&Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| CN-102480964-A | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME | 2012-05-30 | — | — | CN | disclosed |
| CN-101472899-A | 2-substituted 4-benzylphthalazinone derivatives as histamine H1 and H3 antagonists | GLAXO GROUP LTD (GB) | 2009-07-01 | — | — | CN | disclosed |
| WO-2009060209-A1 | 6,6-FUSED BICYCLIC AROMATIC COMPOUNDS AND THEIR THERAPEUTI USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | IDO1 595/4885LMNA 4038/4885CYP2A6 2845/4885 |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | IDO1 715/4885LMNA 3981/4885CYP2A6 2723/4885 |
| US-20160052892-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | P2RX3, P2RX6, P2RX2 | IDO1 1701/4885LMNA 2851/4885CYP2A6 133/4885 |
| US-20130225596-A1 | NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) | P2RX3, P2RX6, P2RX2 | IDO1 1701/4885LMNA 2851/4885CYP2A6 133/4885 |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | IDO1 697/4885LMNA 4047/4885CYP2A6 2248/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | IDO1 697/4885LMNA 4047/4885CYP2A6 2248/4885 |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | IDO1 595/4885LMNA 4038/4885CYP2A6 2845/4885 |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, SYK | IDO1 694/4885LMNA 4037/4885CYP2A6 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.